P1.17-22 Do Statins Improve Outcomes After Radical Radiotherapy for Lung Cancer? An In-Depth Analysis of Over 1100 Patients

Background: Statins exhibit anti-cancer activity in vitro in addition to cardiovascular protection effects. Trials using statins in lung cancer have shown mixed results. This study investigates statins' impact on patients treated with curative radiotherapy for lung cancer. Method(s): All patients who received radical radiotherapy for lung cancer from 01/01/2010-31/12/2016 at a large cancer centre were included. Individual patient information, including drug history at diagnosis, has been retrieved from hospital electronic database. Pre-existing cardiac conditions, Charlson Co-mobidity index and Qrisk3 scores were calculated. Result(s): 1181 patients were identified. Patient and treatment demographics are summarised in table 1. Patients in the statin group were older, had more co-morbidities and higher Qrisk3 scores. For the whole patient population, being on stains at the time of diagnosis was not significantly associated with better Overall Survival (OS) or Progression Free Survival (PFS). A 'High Risk Cohort'(HRC) was identified, which consists of patients with a history of cardiac disease or Qrisk3 score >40. In HRC, statins significantly improved OS and PFS (p=0.016 and p=0.031 respectively), Graph 1. [Figure presented] [Figure presented] Conclusion(s): In this retrospective analysis, patients who were on statins in the HRC had better survival outcomes, despite being older and have more comobidities. Mechanism of action of statins in lung cancer remains unclear and may be different in the post radiotherapy setting. Prospective studies would be useful to evaluate statins in this setting. Keywords: radiotherapy, Statins, CardiotoxicityCopyright © 2019